Skip to main content

Advertisement

Table 1 Demographic and clinical characteristics of the study population (n = 15)

From: 18F-FDG and 68Ga-somatostatin analogs PET/CT in patients with Merkel cell carcinoma: a comparison study

Patient Gender, Age (years) Site of MCC at diagnosis MCC stage at diagnosis Previous surgery for MCC Previous treatment, time between previous treatment and PET/CT (months) Associated malignancy Clinical indication for PET/CT
Primary MCC Unknown primary MCC
1 M, 74 Ear   III Primary tumor excisional biopsy Prostate cancer + chronic lymphocytic leukemia Staging
2* M, 72 Thigh IV Surgical excision + lymph node excisional biopsy CHT (1) Re-staging#
3 M, 74 Arm III Surgical excision + loco-regional lymphadenectomy CHT (8) Re-staging§
4 M, 80   Inguinal lymph node III Lymph node excisional biopsy Colorectal cancer + cutaneous melanoma Staging
5 F, 80 Cheek   III Surgical excision + loco-regional lymphadenectomy Chronic myeloid leukemia Post-surgical evaluation
6 M, 73 Hand III Surgical excision + loco-regional lymphadenectomy Re-staging§
7 M, 47 Cheek II Primary tumor excisional biopsy Staging
8 M, 71   Inguinal lymph node III Lymph node excisional biopsy CHT (1) Post-CHT evaluation
9 M, 58 Thigh   III Surgical excision + loco-regional lymphadenectomy Post-surgical evaluation
10* M, 79 Back III Surgical excision + loco-regional lymphadenectomy CHT (4) Pancreatic NET Post-CHT evaluation
11* M, 81 Thigh III Surgical excision + sentinel lymph node biopsy RT (10) Cutaneous melanoma Re-staging§
12 F, 41 Gluteus II Surgical excision Post-surgical evaluation
13 F, 70   Inguinal lymph node III Lymph node excisional biopsy Staging
14* M, 80   Femoral lymph node III Lymph node excisional biopsy RT (72) Re-staging#
15* M, 74 Gluteus   IV Surgical excision + loco-regional lymphadenectomy RT (96), CHT (1) Post-CHT evaluation
  1. MCC Merkel cell carcinoma, PET/CT positron emission tomography/computed tomography, M male, F female, CHT chemotherapy, RT radiotherapy
  2. *Patient with recurrent/relapsed MCC
  3. #For clinical progression
  4. §For suspected recurrence at imaging